You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The early-stage company just launched a bioinformatics security service, but it is developing technology to label and manage individual molecules in DNA samples.
The Dutch bioinformatics firm's ImmunoGenomiX technology platform is helping researchers develop therapies for COVID-19 as well as for cancer.
The firm said it will use the financing for ongoing development of software and learning models.
The partnership will integrate Milaboratories' MiXCR software into Enpicom's ImmunoGenomix platform for immune repertoire sequencing.
The new CompStor Insight combines hardware and software in one plug-and-play package and complements the vendor's Novos DNA assembly tool.
Bioinformatics firm M2Gen will analyze whole-exome sequencing and tumor RNA-seq data for the HudsonAlpha genomic lab affiliate.
Data privacy firm Oasis Labs will offer a consumer-controlled data management app to customers of the DNA testing company, which was cofounded by George Church.
The integration on the Microsoft Azure cloud is helping Kaiser make its vast genomics dataset available to a wider pool of researchers.
Up to 35 private and public labs in France will be able to use UgenTec's FastFinder analysis software to scale up testing for SARS-CoV-2 and other pathogens.
Belgium's OncoDNA believes that IntegraGen's bioinformatics platform will help it manage more cancer patient data and quickly generate patient-specific treatment reports for clinicians.
Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.
23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.